Login to Your Account

AstraZeneca Oncology Deal Could Bring Abgenix $500M

By Kim Coghill

Friday, October 17, 2003
AstraZeneca entered antibody biotechnology Thursday through a collaboration that could land partner Abgenix Inc. $500 million, all for discovering and developing fully human monoclonal antibodies to treat cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription